文献速递湿疹皮炎与荨麻疹

系统免疫调节药物治疗特应性皮炎二元疗效比较:活系统评价与网络Meta分析

Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.
PubMed 文献 · Br J Dermatol · 2024-01-01

在8-16周成人为主的试验中,upadacitinib 30 mg每日和abrocitinib 200 mg每日的二元疗效终点最有效,其次为upadacitinib 15 mg每日、dupilumab和abrocitinib 100 mg每日。

要点

  • upadacitinib 30 mg每日和abrocitinib 200 mg每日在8-16周成人中重度AD的二元疗效终点最有效。
  • dupilumab和两种剂量的upadacitinib及abrocitinib优于baricitinib 4和2 mg每日及tralokinumab。
  • 结果与既往连续疗效指标的分析结果一致。

核心结论

  • upadacitinib 30 mg每日和abrocitinib 200 mg每日在成人中重度AD的二元疗效终点(至16周)最有效,其次为upadacitinib 15 mg每日、dupilumab和abrocitinib 100 mg每日。
  • dupilumab和两种剂量的upadacitinib及abrocitinib优于baricitinib 4和2 mg每日及tralokinumab。

研究设计与样本

  • 活系统评价与网络Meta分析,检索CENTRAL、MEDLINE、Embase、LILACS、GREAT数据库及试验注册库至2023年3月1日。
  • 采用随机效应贝叶斯网络Meta分析计算各干预间各结局的OR和95% CrI。

主要发现

  • 在8-16周且以成人为主的试验中,abrocitinib 200 mg每日(OR 1.5,95% CrI 1.1-2.2)和upadacitinib 15 mg每日(OR 1.7,95% CrI 0.9-3.3)及30 mg每日(OR 2.5,95% CrI 1.3-5.0)相比dupilumab与更高的EASI 50达标几率相关。
  • abrocitinib 100 mg每日(OR 0.7,95% CrI 0.5-1.0)、baricitinib 2 mg每日(OR 0.4,95% CrI 0.3-0.5)和4 mg每日(OR 0.5,95% CrI 0.3-0.7)以及tralokinumab(OR 0.4,95% CrI 0.3-0.6)相比dupilumab与更低的EASI 50达标几率相关。
  • EASI 75、EASI 90和IGA成功的结果与EASI 50相似。

关键数值与推荐

  • EASI 50、EASI 75、EASI 90和IGA成功为二元疗效结局指标。
  • 在8-16周成人为主的试验中,abrocitinib 200 mg每日相比dupilumab的EASI 50 OR为1.5(95% CrI 1.1-2.2)。
  • upadacitinib 15 mg每日相比dupilumab的EASI 50 OR为1.7(95% CrI 0.9-3.3),30 mg每日OR为2.5(95% CrI 1.3-5.0)。
  • abrocitinib 100 mg每日相比dupilumab的EASI 50 OR为0.7(95% CrI 0.5-1.0)。
  • baricitinib 2 mg每日相比dupilumab的EASI 50 OR为0.4(95% CrI 0.3-0.5),4 mg每日OR为0.5(95% CrI 0.3-0.7);tralokinumab相比dupilumab OR为0.4(95% CrI 0.3-0.6)。

临床怎么用

  • 在成人中重度AD的8-16周治疗决策中,upadacitinib 30 mg每日和abrocitinib 200 mg每日在二元疗效终点上显示最有效。
  • dupilumab和两种剂量的upadacitinib及abrocitinib在二元疗效终点上优于baricitinib 4和2 mg每日及tralokinumab。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic treatments for atopic dermatitis (AD) are evaluated primarily in placebo-controlled trials with binary efficacy outcomes. In a living systematic review and network meta-analysis (NMA), we previously analysed continuous efficacy measures. OBJECTIVES: To compare binary efficacy outcomes of systemic treatments for AD. METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Latin American and Caribbean Health Science Information (LILACS) database, Global Resource for Eczema Trials (GREAT) database and trial registries up to 1 March 2023. We included randomized trials examining ≥ 8 weeks of treatment with systemic immunomodulatory medications for moderate-to-severe AD. We screened titles, abstracts and full texts and abstracted data independently, in duplicate. Outcomes included the proportion of patients achieving at least 50%, 75% and 90% improvements in Eczema Area and Severity Index (EASI 50, EASI 75 and EASI 90, respectively) and Investigator Global Assessment (IGA) success. We performed random-effects Bayesian NMAs to calculate odds ratios (OR) and 95% credible intervals (CrIs) between each intervention for each outcome. RESULTS: Eighty-three trials with 22 122 participants were included in the systematic review. In analyses limited to trials of 8-16 weeks' duration with predominantly adult populations, abrocitinib 200 mg daily (OR 1.5, 95% CrI 1.1-2.2) and upadacitinib 15 mg daily (OR 1.7, 95% CrI 0.9-3.3) and 30 mg daily (OR 2.5, 95% CrI 1.3-5.0) were associated with higher odds of achieving EASI 50 vs. dupilumab. Abrocitinib 100 mg daily (OR 0.7, 95% CrI 0.5-1.0), baricitinib 2 mg daily (OR 0.4, 95% CrI 0.3-0.5) and 4 mg daily (OR 0.5, 95% CrI 0.3-0.7), and tralokinumab (OR 0.4, 95% CrI 0.3-0.6) were associated with lower odds of achieving EASI 50 vs. dupilumab. Results were similar for EASI 75, EASI 90 and IGA success. CONCLUSIONS: Supporting results for continuous outcome measures, upadacitinib 30 mg daily and abrocitinib 200 mg daily are the most efficacious with regard to binary efficacy endpoints up to 16 weeks in adults with moderate-to-severe AD, followed by upadacitinib 15 mg daily, dupilumab and abrocitinib 100 mg daily. Dupilumab and both doses of upadacitinib and abrocitinib are more efficacious than baricitinib 4 and 2 mg daily and tralokinumab.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Drucker AM, Lam M, Elsawi R, et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol. 2024. PMID: 37831594. doi:10.1093/bjd/ljad393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。